{
    "relation": [
        [
            "Arms",
            "Experimental: Indacaterol 18.75 \u03bcg Patients inhaled indacaterol 18.75 \u03bcg once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.",
            "Experimental: Indacaterol 37.5 \u03bcg Patients inhaled indacaterol 37.5 \u03bcg once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.",
            "Experimental: Indacaterol 75 \u03bcg Patients inhaled indacaterol 75 \u03bcg once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.",
            "Experimental: Indacaterol 150 \u03bcg Patients inhaled indacaterol 150 \u03bcg once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.",
            "Active Comparator: Salmeterol 50 \u03bcg Patients inhaled salmeterol 50 \u03bcg twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. In addition, patients inhaled placebo to indacaterol once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study.",
            "Placebo Comparator: Placebo Patients inhaled placebo to indacaterol once daily in the morning via the Concept1 single-dose dry-powder inhaler (SDDPI). In addition, patients inhaled placebo to salmeterol twice daily, once in the morning and once in the evening, via the manufacturer's proprietary Diskus inhaler. Treatment continued for 2 weeks. Daily inhaled corticosteroid treatment (if applicable) was to remain stable throughout the study. Albuterol via a multi-dose dry-powder inhaler (MDI) was available for rescue use throughout the study."
        ],
        [
            "Assigned Interventions",
            "Drug: Indacaterol Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device. Drug: Placebo to salmeterol Placebo to salmeterol was supplied in the manufacturer's proprietary Diskus inhaler device.",
            "Drug: Indacaterol Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device. Drug: Placebo to salmeterol Placebo to salmeterol was supplied in the manufacturer's proprietary Diskus inhaler device.",
            "Drug: Indacaterol Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device. Drug: Placebo to salmeterol Placebo to salmeterol was supplied in the manufacturer's proprietary Diskus inhaler device.",
            "Drug: Indacaterol Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device. Drug: Placebo to salmeterol Placebo to salmeterol was supplied in the manufacturer's proprietary Diskus inhaler device.",
            "Drug: Salmeterol 50 \u03bcg Salmeterol was supplied in the manufacturer's proprietary Diskus inhaler device. Drug: Placebo to indacaterol Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.",
            "Drug: Placebo to indacaterol Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device. Drug: Placebo to salmeterol Placebo to salmeterol was supplied in the manufacturer's proprietary Diskus inhaler device."
        ]
    ],
    "pageTitle": "Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) - Full Text View - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/NCT01089127",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 3,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042986444.39/warc/CC-MAIN-20150728002306-00137-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 852852854,
    "recordOffset": 852837197,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "July 2010 (Final data collection date for primary outcome measure) Primary Completion Date: July 2010 Study Completion Date: March 2010 Study Start Date: 552 Enrollment: Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose on Day 2 [\u00a0Time\u00a0Frame:\u00a024 hours post-dose on Day 2\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0] Secondary Outcome Measures: FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose on Day 2. The analysis included baseline FEV1, FEV1 pre-dose and 10-15 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates. FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose at the end of treatment. The analysis included baseline FEV1, FEV1 pre-dose and 10-15 minutes post-dose of",
    "textAfterTable": "\u00a0 Eligibility Ages Eligible for Study: \u00a0 40 Years and older Genders Eligible for Study: \u00a0 Both Accepts Healthy Volunteers: \u00a0 No Criteria Inclusion criteria: Diagnosis of chronic obstructive pulmonary disease (COPD) (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease [GOLD] Guidelines, 2008) and: Smoking history of at least 10 pack-years Post-bronchodilator forced expiratory volume in 1 second (FEV1) < 80% and \u2265 30% of the predicted normal value Post-bronchodilator FEV1/FVC (forced vital capacity) < 70% Exclusion criteria: Patients who have had a COPD exacerbation requiring systemic corticosteroids and/or antibiotics and/or hospitalization in the 6 weeks prior to screening Patients who have had a respiratory tract infection within 6 weeks prior to screening Patients with concomitant pulmonary disease Patients with a history of asthma Patients with diabetes Type I or uncontrolled diabetes Type II Any patient with",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}